MM-141

Merrimack Pharmaceuticals Inc (NASDAQ: MACK) plunged more than 30 percent Monday after management discontinued the development of MM-141. The drug’s Phase 2 trial for MM-141 in front-line metastatic pancreatic cancer did not meet primary or secondary endpoints. Why It’s Important...